Effect of CER-001 on blockage of arteries (plaque) in subjects with homozygous familial hypercholesterolemia

Registry ID

EUCTR2011-003998-28

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

CERENIS THERAPEUTICS SA

Start date

2012-02-16

Completion date

2014-07-08

Last update

2026-08-16

Conditions

• homozygous familial hypercholesterolemia

Summary

To assess the impact of 12 intravenous infusions of 8 mg/kg CER-001 given at 2-week intervals on descending thoracic aorta and carotid plaque volume, determined from vessel wall volume of diseased arterial segments using 3T magnetic resonance imaging (3TMRI).

Locations

• , , UK
• , , Netherlands
• , , Italy

Related clinical trials

• Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19)

View on source registry